Plain English Summary
Background and study aims
Irritable bowel syndrome (IBS) is a common, long-term disorder of the digestive system. It is part of a group of disorders called functional bowel disorders, as it affects the way the bowel (intestines) functions. IBS is associated with a number of digestive symptoms such as abdominal pain, diarrhoea, constipation and flatulence, which vary from person to person. The use of probiotics (live bacteria that are good for health as they replenish “good” bacteria that help the digestive system to work properly) has been shown to have beneficial effects on the health of people with IBS. The aim of this study is to compare two different probiotic mixtures in their effectiveness at treating irritable bowel syndrome with constipation (IBS-C).
Who can participate?
Adults with IBS-C.
What does the study involve?
Participants are randomly allocated to one of three groups. Those in the first group take capsules containing the first probiotic mix, which contains the bacteria Lactobacillus acidophilus and Lactobacillus reuteri, once a day for 60 days. Those in the second group group take capsules containing the first probiotic mix, which contains the bacteria Lactobacillus plantarum, Lactobacillus rhamnosus and Bifidobacterium animalis subspecies lactis, once a day for 60 days. Those in the third group take capsules containing a placebo (dummy) once a day for 60 days. All participants provide stool samples at the start of the study and then again after 10, 30, 60 and 90 days in order to measure the composition of the bacteria in the gut. At the same times, participants also complete a questionnaire about the IBS-C related symptoms they are having.
What are the possible benefits and risks of participating?
Participants who take the probiotic mixtures may benefit from an improvement to their IBS symptoms. There are no notable risks involved with taking part in this study.
Where is the study run from?
Farcoderm Clinic (Italy)
When is the study starting and how long is it expected to run for?
July 2013 to January 2015
Who is funding the study?
Ministry of Education, Universities and Research (Italy)
Who is the main contact?
Dr Anela Michelotti
MI.02.DS.L_2013/PROBIOPLUS 4 FOOD
Effects of multispecies probiotic supplementation on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial
The aim of this study is to compare the clinical efficacy of two multispecies probiotic formulates, in particular their beneficial role in the functional bowel disorders will be state in comparison with a placebo.
Independent Ethical Committee for Non-Pharmacological Clinical studies, 17/07/2013
Randomized double-blind three-arm placebo-controlled trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details to request a patient information sheet
Irritable bowel syndrome associated constipation (IBS-C)
For the study 150 adult subjects, diagnosed with irritable bowel syndrome associated to constipation (IBS-C) were enrolled and divided in three groups (F_1, F_2, F_3). Each group received a daily oral administration of different probiotic mixtures (for a total period of 60 days). Participants are randomly allocated to one of three groups:
Group 1: Participants receive probiotics mix F_1 (Lactobacillus acidophilus and Lactobacillus reuteri) capsules to take once daily for 60 days.
Group 2: Participants receive probiotics mix F_2 (Lactobacillus plantarum, Lactobacillus rhamnosus and Bifidobacterium animalis subsp. lactis) capsules to take once daily for 60 days.
Group 3: Participants receive a placebo in the form of mix F_3 capsules to take once daily for 60 days.
Participants in all groups are followed for a further period of 30 days after a follow-up period from the last
ingestion of the tested products; during this period they doesn’t take anything.
Primary outcome measure
1. IBS-C symptoms are measured using the IBS-C questionnaire of related symptoms, which consists of five items (bloating, abdominal pain, constipation, abdominal cramps and flatulence) scored on a 10-point Visual Analogue Scale (VAS) at baseline, 10, 30 and 60 days
2. Gut colonization is determined through fecal microbiological analyses using species-specific qPCR on stool samples collected at baseline, 10, 30 and 60 days
Secondary outcome measures
Maintenance of the obtained effects are measured using IBS-C symptoms questionnaire microbiological analyses performed by species-specific qPCR 30 days after the last product(s) intake.
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Aged between 18 and 65 years old
2. Suffering from Irritable Bowel Syndrome with constipation (IBS-C)
Target number of participants
Participant exclusion criteria
1. Pregnancy or intention to become pregnant during the study period
3. Food intolerances/allergy
4. Known history of gastro-intestinal disorders
5. Chronic or acute gastrointestinal disorders
6. Participation in another similar study
7. Unwillingness or inability to comply with the study protocol requirements
8. Currently using food supplements or drugs containing actives having an influence on gastro-intestinal physiology
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Farcoderm Clinic (Farcoderm Poliambulatorio)
Via Mons. Angelini, 21
San Martino Siccomario (PV)
Ministero dell’Istruzione, dell’Università e della Ricerca
Ministry of Education, Research and Universities, MIUR
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in BioMed Research International (Hindawi Publishing Corporation).
Intention to publish date
Participant level data
Available on request
Basic results (scientific)
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27595104